These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1877192)

  • 61. [Indication for use and mechanisms of action of intravenous immune globulin in autoimmune diseases].
    Cohen AD; Shoenfeld Y
    Harefuah; 1995 Aug; 129(3-4):123-7. PubMed ID: 8543238
    [No Abstract]   [Full Text] [Related]  

  • 62. An assessment of the safety and tolerability of immune globulin intravenous (human) Sandoglobulin prepared in sterile water or 5% dextrose at various concentrations.
    Miller KB; Schenkein DP; Fogaren T
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):109-11. PubMed ID: 1509290
    [No Abstract]   [Full Text] [Related]  

  • 63. [Recent developments in high-dose immunoglobulin therapy: therapeutic plasma exchange, autoimmune diseases].
    Kalden JR; Schranz W; Lösch G; Krapf F; Bartels O
    Beitr Infusionther Klin Ernahr; 1982; 9():48-59. PubMed ID: 6216881
    [No Abstract]   [Full Text] [Related]  

  • 64. Classification of immunotherapeutic agents.
    Hadden JW
    Dev Biol Stand; 1992; 77():5-15. PubMed ID: 1426673
    [No Abstract]   [Full Text] [Related]  

  • 65. Levamisole as immunostimulant in the clinical practice.
    Pár A
    Ther Hung; 1983; 31(4):161-71. PubMed ID: 6546263
    [No Abstract]   [Full Text] [Related]  

  • 66. Systemic and topical immunoglobulin treatment in immunocompromised patients.
    Hammarström L; Gardulf A; Hammarström V; Janson A; Lindberg K; Smith CI
    Immunol Rev; 1994 Jun; 139():43-70. PubMed ID: 7523279
    [No Abstract]   [Full Text] [Related]  

  • 67. Indications for use of intravenous immunoglobulin. Recommendations of the Australasian Society of Blood Transfusion consensus symposium.
    Keller T; McGrath K; Newland A; Gatenby P; Cobcroft R; Gibson J
    Med J Aust; 1993 Aug; 159(3):204-6. PubMed ID: 8336623
    [No Abstract]   [Full Text] [Related]  

  • 68. [Perspectives in the therapeutic use of human immunoglobulins].
    Touraine JL
    Presse Med; 1983 Nov; 12(41):2560-2. PubMed ID: 6228790
    [No Abstract]   [Full Text] [Related]  

  • 69. Subcutaneous immunoglobulin loading regimens for previously untreated patients with primary antibody deficiency.
    Rojavin M; Sidhu J; Pfister M; Hubsch A
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):146-8. PubMed ID: 25546799
    [No Abstract]   [Full Text] [Related]  

  • 70. Another subcutaneous immune globulin (Cuvitru) for primary immunodeficiency.
    Med Lett Drugs Ther; 2017 May; 59(1521):e88-e89. PubMed ID: 28520701
    [No Abstract]   [Full Text] [Related]  

  • 71. A preliminary trial of high-dose intravenous immunoglobulin to a patient with euthyroid ophthalmopathy.
    Philipsen EK; Larsen S; Helin P
    Thyroidology; 1989 Aug; 1(2):93-5. PubMed ID: 2484869
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synergy between plasma exchange and intravenous immunoglobulin.
    Nydegger UE; Rieben R; Jungi TW
    Curr Stud Hematol Blood Transfus; 1990; (57):31-50. PubMed ID: 2148718
    [No Abstract]   [Full Text] [Related]  

  • 73. Intravenous immune globulin for treating primary immunodeficiency disease.
    Miller DS
    MCN Am J Matern Child Nurs; 1987; 12(4):244-8. PubMed ID: 3112495
    [No Abstract]   [Full Text] [Related]  

  • 74. Immunoglobulin replacement therapy by slow subcutaneous infusion.
    Berger M; Cupps TR; Fauci AS
    Ann Intern Med; 1980 Jul; 93(1):55-6. PubMed ID: 7396316
    [No Abstract]   [Full Text] [Related]  

  • 75. Subcutaneous immunoglobulin for patients with antibody deficiency.
    Helbert M; Farragher A
    Br J Hosp Med (Lond); 2007 Apr; 68(4):206-10. PubMed ID: 17465102
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Home treatment of antibody-deficiency syndromes with intravenous immune globulin.
    Sorensen RU; Kallick MD; Berger M
    J Allergy Clin Immunol; 1987 Dec; 80(6):810-5. PubMed ID: 3693759
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [What can one expect of immunostimulants in the clinical setting?].
    Bach JF
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):233-6. PubMed ID: 3539497
    [TBL] [Abstract][Full Text] [Related]  

  • 78. B cell immunology for the clinician.
    Marcus C; Dhillon G; Anolik JH
    Pediatr Infect Dis J; 2011 Feb; 30(2):158-60. PubMed ID: 21242750
    [No Abstract]   [Full Text] [Related]  

  • 79. Distribution plan for immune globulin intravenous during a shortage.
    Connelly JF; Verzino KC
    Am J Health Syst Pharm; 1999 Aug; 56(15):1546-8. PubMed ID: 10478995
    [No Abstract]   [Full Text] [Related]  

  • 80. Advanced lung disease in a patient with cystic fibrosis and hypogammaglobulinemia: response to intravenous immune globulin therapy.
    Bentur L; McKlusky I; Levison H; Roifman CM
    J Pediatr; 1990 Nov; 117(5):741-3. PubMed ID: 2231205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.